Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli
Acta Microbiologica et Immunologica Hungarica · 2024
DOI: 10.1556/030.2024.02292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Microbiologica et Immunologica Hungarica, 2024. Verfasst von Sevil Öztaş und 3 weiteren Autor:innen. Beteiligte Einrichtung: 1Vocational School of Health Services, Karabuk University, Karabük, 78600, Türkiye. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Ceftazidime, Azabicyclo Compounds, Drug Combinations. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Kocaeli University Scientific Research Projects Coordination Unit.
Abstract (Originalsprache)
Carbapenem-resistant Enterobacterales (CRE) have become a major public health problem worldwide. The aim of this study was to investigate efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli isolates. Susceptibility of imipenem, meropenem, ertapenem, ceftazidime/avibactam and plazomicin was investigated by broth-microdilution method. Major carbapenemases NDM, VIM, IMP, KPC, OXA-48 as well as other β-lactamases namely, TEM, SHV, OXA-1-like, CTX-M, ACC, FOX, MOX, DHA, CIT, EBC, VEB, GES, PER were investigated by PCR. A total of 120 carbapenem-resistant isolates (60 E. coli and 60 K. pneumoniae ) were included in this study and bla OXA-48-like was found in 78.33%, bla NDM in 26.66%, bla KPC in 7.5%, bla IMP in 5.83%, and bla VIM in 5%. Among 94 isolates with the bla OXA-48-like gene, 22.3% were resistant to ceftazidime/avibactam and 51.1% were resistant to plazomicin. Of 32 isolates with bla NDM , 31 (96.9%) were resistant to ceftazidime/avibactam and 30 (93.75%) were resistant to plazomicin, and both antibiotics had limited effects against bla NDM carriers ( P < 0.001). Of the 12 isolates with bla NDM+OXA-48 combination, 11 (91.7%) were resistant to ceftazidime/avibactam and plazomicin. The effect of both antibiotics was significantly lower in strains with bla NDM+OXA-48 combination ( P < 0.005). The most common carbapenemase genes in this study were bla OXA-48-like and bla NDM . Ceftazidime/avibactam demonstrated a good efficacy among OXA-48 producing K. pneumoniae and E. coli , however, plazomicin had a significantly lower antibacterial effect in our study. Both antimicrobial agents should be considered as an option by evaluating combined susceptibility results and gene patterns obtained by regional and global molecular data in the treatment of CRE infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Vocational School of Health Services, Karabuk University, Karabük, 78600, Türkiye.
- 2Molecular Gastroenterology and Hepatology Department, Gastroenterology and Hepatology Institute, Kocaeli University, Kocaeli, 41000, Türkiye.
- 3Medical Microbiology Department Faculty of Medicine, Kocaeli University, Kocaeli, 41000, Türkiye.
ORCID-Profile: Sevil Öztaş
Förderung
- Kocaeli University Scientific Research Projects Coordination Unit
Zitieren
APA
Öztaş, S., Er, D. K., Dündar, D., & Keçeli, S. A. (2024). Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli. Acta Microbiologica et Immunologica Hungarica. https://doi.org/10.1556/030.2024.02292
Vancouver
Öztaş S, Er DK, Dündar D, Keçeli SA. Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli. Acta Microbiologica et Immunologica Hungarica. 2024. doi:10.1556/030.2024.02292
BibTeX
@article{zta2024,
author = {Öztaş, Sevil and Er, Doğanhan Kadir and Dündar, Devrim and Keçeli, Sema Aşkın},
title = {Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli},
journal = {Acta Microbiologica et Immunologica Hungarica},
year = {2024},
doi = {10.1556/030.2024.02292}
}
EUVIMED